

Docket No. 23623-7078
GC Ref. No. 568-2-D1

Certificate of Mailing/Transmission (37 C.F.R. § 1.10(a)):

[X] Pursuant to 37 C.F.R. § 1.10, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" (EL710203395US) on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Box New Application, Washington D.C. 20231.

[] Pursuant to 37 C.F.R. § 1.6(d), I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of Examiner _____ at Facsimile No. _____ at _____ a.m./p.m.

Dated: February 12, 2002

Name of Person Certifying: Nancy Hine
Printed Name: Nancy Hine

4/a
H.Q.
3/29/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Davis et al.	Assignee:	Genencor International, Inc.
Filing Date:	Herewith	Examiner:	Not Yet Assigned
Serial No.:	Unknown	Group Art Unit:	Not Yet Assigned
Title:	CHEMICALLY MODIFIED ENZYMES WITH MULTIPLE CHARGED VARIANTS		

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please enter the following Preliminary Amendment for the above-identified patent application which is a divisional of Ser. No. 09/467,536, filed December 20, 1999, and claims the benefit of U.S. Provisional Patent Application No. 60/113,130, December 21, 1998.

IN THE SPECIFICATION

Please replace the paragraph beginning at 1:4 with the following rewritten paragraph:

*45
8/19/02
a*
now US Pat 6,379,942
—This application is a divisional of Ser. No. 09/467,536, filed December 20, 1999, pending, which claims the benefit of U.S. Provisional Patent Application No. 60/113,130, filed December 21, 1998, abandoned, the entire disclosures of which are hereby incorporated by reference in their entirety for all purposes.—

Please replace the paragraph beginning at 11:17 with the following rewritten paragraph:

a²
—Figures 4A, 4B, 4C, and 4D illustrate altered specificity patterns relative to WT as the level of negative charge increases in N62C, L271C, S156C and S166C mutants and CMMs with suc-AAPF-pNA as the substrate: Figure 4A: The k_{cat}/K_M s for N62C CMMs alternate at moderately reduced levels, 1.5- to 3.5-fold lower than WT, which are established by the initial mutation to N62C (R=H). Figure 4B: L217C CMMs show steady but lower levels of k_{cat}/K_M , 4- to 5.5-fold lower than WT, which are again established by the initial mutation to